Instrument Inactif

Communiqués Cleveland BioLabs, Inc. Nasdaq

Actions

US1858601032

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

31/08/21	Cytocom change de nom et devient Statera BioPharma	MT
16/08/21	Cleveland Biolabs, Inc. annonce ses résultats pour le deuxième trimestre clos le 30 juin 2021	CI

Communiqués

14/06/22	Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm	GL
23/05/22	Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing	GL
13/05/22	Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products	GL
27/04/22	Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone	GL
13/04/22	Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod	GL
31/03/22	Statera Biopharma, Inc. Files Form 12b-25	GL
24/03/22	Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering	GL
22/03/22	Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering	GL
22/03/22	CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering	GL
08/03/22	Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021	GL
02/03/22	CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19	GL
15/02/22	Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease	GL
22/09/21	Statera Biopharma : to Participate in the Benzinga Healthcare Small Cap Conference	PR
21/09/21	Statera Biopharma : to Participate in the Cantor Virtual Global Healthcare Conference	PR
01/09/21	Cleveland Biolabs : OF RESTATED CERTIFICATE OF INCORPORATION (Form 8-K)	PU
17/08/21	CYTOCOM, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
16/08/21	Cleveland Biolabs : CYTOCOM, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
09/08/21	CYTOCOM, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
02/08/21	CYTOCOM, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
30/07/21	Cleveland Biolabs : CYTOCOM, INC. Financial Statements and Exhibits (form 8-K/A)	AQ
29/07/21	Cytocom, Inc. : Receives Commitments for $90 Million in Equity and Debt Financing	PR
28/07/21	Cleveland BioLabs : Cytocom Inc. Announces Completed Merger with Cleveland BioLabs (Form 8-K)	PU
28/07/21	CLEVELAND BIOLABS INC : Completion of Acquisition or Disposition of Assets, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/07/21	CLEVELAND BIOLABS INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
06/07/21	Cleveland BioLabs : and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger	PR